Abstract
Among the drugs targeting microtubule functions by interfering with tubulin subunits, epothilones represent a class of anticancer agents which recently entered clinical development. Although epothilones share mechanisms of action similar to taxanes, they have non-overlapping mechanisms of resistance; in particular, while overexpression of class III β-tubulin plays a major role in taxane resistance, epothilones display their highest efficacy in class III β-tubulin overexpressing malignancies. Three compounds belonging to this family (patupilone, ixabepilone and sagopilone), have been actively investigated in clinical trials, and some of them are at an advanced stage of development.
This review provides a comprehensive analysis of the available literature on epothilones, focusing on their clinical development and potential as an additional weapon in the arsenal against tumors.
Keywords: Epothilones, cytoskeleton, class III β-tubulin, cell survival, ovarian cancer, anticancer agents, taxane resistance, tumors, p-glycoprotein, microtubule
Current Pharmaceutical Design
Title:Novel Drugs Targeting Microtubules: the Role of Epothilones
Volume: 18 Issue: 19
Author(s): Gabriella Ferrandina, Marisa Mariani, Mirko Andreoli, Shohreh Shahabi, Giovanni Scambia and Cristiano Ferlini
Affiliation:
Keywords: Epothilones, cytoskeleton, class III β-tubulin, cell survival, ovarian cancer, anticancer agents, taxane resistance, tumors, p-glycoprotein, microtubule
Abstract: Among the drugs targeting microtubule functions by interfering with tubulin subunits, epothilones represent a class of anticancer agents which recently entered clinical development. Although epothilones share mechanisms of action similar to taxanes, they have non-overlapping mechanisms of resistance; in particular, while overexpression of class III β-tubulin plays a major role in taxane resistance, epothilones display their highest efficacy in class III β-tubulin overexpressing malignancies. Three compounds belonging to this family (patupilone, ixabepilone and sagopilone), have been actively investigated in clinical trials, and some of them are at an advanced stage of development.
This review provides a comprehensive analysis of the available literature on epothilones, focusing on their clinical development and potential as an additional weapon in the arsenal against tumors.
Export Options
About this article
Cite this article as:
Ferrandina Gabriella, Mariani Marisa, Andreoli Mirko, Shahabi Shohreh, Scambia Giovanni and Ferlini Cristiano, Novel Drugs Targeting Microtubules: the Role of Epothilones, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626238
DOI https://dx.doi.org/10.2174/138161212800626238 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Progesterone Receptor Membrane Component 1 and its Accomplice: Emerging Therapeutic Targets in Lung Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Radioiodinated Ginger Compounds (6-gingerol and 6-shogaol) and Incorporation Assays on Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cancer-Homing Toxins
Current Pharmaceutical Design Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders Nanoparticle Engineering Enhances Anticancer Efficacy of Andrographolide in MCF-7 Cells and Mice Bearing EAC
Current Pharmaceutical Biotechnology Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine Targeting Human Telomerase in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Estrogen Receptor Modulators: Relationships of Ligand Structure, Receptor Affinity and Functional Activity
Current Topics in Medicinal Chemistry Variances in the Expression Profile of the EMT-Related Genes in Endometrial Cancer Lines <i>In Vitro</i> Study
Current Pharmaceutical Biotechnology Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of Female Fertility and Identification of Future Contraceptive Targets
Current Pharmaceutical Design Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design